Gemmer Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Gemmer Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-12	Closed	–	–	323
2022 Q1	$0	Hold	12	–	–	﹤0.01%	1237
2021 Q4	$1K	Sell	12 -13	-52%	-$1.14K	﹤0.01%	1212
2021 Q3	$3K	Hold	25	–	–	﹤0.01%	1104
2021 Q2	$4K	Hold	25	–	–	﹤0.01%	1164
2021 Q1	$3K	Sell	25 -244	-91%	-$36.8K	﹤0.01%	1247
2020 Q4	$41K	Buy	269 +219	+438%	+$25.9K	0.01%	265
2020 Q3	$4K	Sell	50 -25	-33%	-$2.22K	﹤0.01%	940
2020 Q2	$6K	Sell	75 -50	-40%	-$2.92K	﹤0.01%	770
2020 Q1	$5K	Buy	+125	New	+$6.45K	﹤0.01%	739
2019 Q1	–	Sell	-200	Closed	-$6K	–	1400
2018 Q4	$6K	Hold	200	–	–	﹤0.01%	818
2018 Q3	$9K	Buy	+200	New	+$10.5K	﹤0.01%	744

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Gemmer Asset Management's CRSP Position: Q2 2022 in Review

Gemmer Asset Management sold out of CRISPR Therapeutics (CRSP) in Q2 2022, closing a stake of 12 shares.

Gemmer Asset Management first reported a position in CRSP in Q3 2018 and held it in 11 quarters. The position peaked at $41K in Q4 2020. 435 funds tracked by Wall St. Rank hold CRSP as of Q2 2022.

Gemmer Asset Management reported no remaining CRISPR Therapeutics position as of Q2 2022 after selling out during the quarter.
Gemmer Asset Management sold 12 CRISPR Therapeutics shares in Q2 2022.
Gemmer Asset Management first reported a position in CRISPR Therapeutics in Q3 2018 and held it in 11 quarters.
Gemmer Asset Management's CRISPR Therapeutics position peaked at $41K in Q4 2020.
435 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2022.

Based on Gemmer Asset Management's 13F filing for Q2 2022, filed 22 Jul 2022.